Study of inhibitory effect of formononetin on human renal carcinoma cell 786-O and its mechanism
CHEN Qing1 LI Haihong2 OU Weining1 ZHANG Xing3
1.Department of Nephrology, the Second People’s Hospital of Yulin, Guangxi Zhuang Autonomous Region, Yulin 537000, China;
2.Department of Quality Control, the First People’s Hospital of Yulin, Guangxi Zhuang Autonomous Region, Yulin 537000, China;
3.Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guangxi Zhuang Autonomous Region, Guilin 541100, China
Abstract Objective To observe the inhibitory effect of formononetin on human renal carcinoma cell 786-O and its mechanism. Methods Human renal carcinoma cell 786-O cultured with different doses of formononetin. They were divided into control group (0 μmol/L, group A), formononetin low-dose group (20 μmol/L, group B), formononetin medium-dose group (40 μmol/L, group C), and formononetin high-dose group (80 μmol/L, group D) according to drug dose. CCK8 method was used to detect the proliferation of four group; apoptosis was detected by flow cytometry and Hoechst staining; the expression of miR-155 was detected by RT-PCR; the protein expressions of P-PI3K and P-AKT were detected by Western blot. Results After 72 h of culture, the inhibitory rate of cell proliferation in groups B, C and D were higher than those in 24 and 48 h of culture. After 48 h of culture, the inhibitory rate of cell proliferation in groups B, C and D were higher than those in 24 h of culture, and the differences were statistically significant (all P < 0.05). After 24, 48 and 72 h of culture, the inhibitory rate of cell proliferation in groups B, C and D were higher than those in group A; groups C and D were higher than that in group B; and group D was higher than that in group C, and the differences were statistically significant (all P < 0.05). The apoptosis rate of four groups were statistically significant (P < 0.05). In group B, C and D, cell shrinkage and nucleus were observed， and the higher the drug dose was, the more obvious the cell apoptosis was; the nucleus of group A was complete and full in morphology. The expression of miR-155 level and P-PI3K and P-AKT proteins levels in groups B, C and D were lower than those in group A, the expression miR-155 level and P-PI3K and P-AKT proteins levels in groups C and D were lower than those in group B, and the expression miR-155 level and P-PI3K and P-AKT proteins levels in group D was lower than that in group C, and the differences were statistically significant (all P < 0.05). Conclusion Formononetin can significantly inhibit proliferation and induce apoptosis in human renal carcinoma cell 786-O, and the mechanism may be related to the down-regulation of miR-155 expression to inhibit the activation of PI3K/AKT signaling pathway.
CHEN Qing1 LI Haihong2 OU Weining1 ZHANG Xing3. Study of inhibitory effect of formononetin on human renal carcinoma cell 786-O and its mechanism[J]. 中国医药导报, 2021, 18(12): 11-15,19.
[1] Li X，Yin A，Zhang W，et al. Jam3 Promotes Migration and Suppresses Apoptosis of Renal Carcinoma Cell Lines [J]. Int J Mol Med，2018，42（5）：2923-2929.
[2] Capitanio U，Montorsi F. Renal cancer [J]. Lancet，2016， 387（10021）：894-906.
[3] Yao JN，Zhang XX，Zhang YZ，et al. Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells [J]. Invest New Drugs，2019， 37（6）：1300-1308.
[4] Zhang J，Liu LK，Wang J，et al. Formononetin，an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells[J]. J Ethnopharmacol，2018，221：91-99.
[5] 柳青，梁梅花，张幸，等.芒柄花黄素对人膀胱癌细胞T739增殖、凋亡的影响及机制探讨[J].中国医药导报，2017，14（25）：4-7.
[6] Sánchez-Gastaldo A，Kempf E，Alba AG，et al. Systemic treatment of renal cell cancer：A comprehensive review [J]. Cancer Treat Rev，2017，60：77-89.
[7] Bacolod MD，Barany F，Pilones K，et al. Chapter Four-Pathways-and epigenetic-based assessment of relative immune infiltration in various types of solid tumors [J]. Adv Cancer Res，2019，142：107-143.
[8] Wang D，Xiao ZJ，Shou JZ，et al. Clinical analysis of 8 cases of the mixed epithelial and stromal tumour family of kidney [J]. Zhonghua Yi Xue Za Zhi，2019，99（10）：771-774.
[9] Park S，Bazer FW，Lim W，et al. The O-methylated isoflavone，formononetin，inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation [J]. J Cell Biochem，2018，119（9）：7377-7387.
[10] Xin M，Wang Y，Ren Q，et al. Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro [J]. Biomed Pharmacother，2019，109：2084-2089.
[11] Tay KC，Tan LT，Chan CK，et al. Formononetin: A Review of Its Anticancer Potentials and Mechanisms [J]. Front Pharmacol，2019，10：820.
[12] Zhang K，Wang YW，Wang YY，et al. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling [J]. Gene，2017，619：10-20.
[13] Dudics S，Venkatesha SH，Moudgil KD. The micro-RNA expression profiles of autoimmune arthritis reveal novel biomarkers of the disease and therapeutic response [J]. Int J Mol Sci，2018，19（18）：2293.
[14] McGeary SE，Lin KS，Shi CY，et al. The biochemical basis of microRNA targeting efficacy [J]. Science，2019， 366（6472）：eaav1741.
[15] Dragomir MP，Knutsen E，Calin GA. SnapShot：Unconventional miRNA Functions [J]. Cell，2018，174（4）：1038-1038.e1.
[16] Shahid S，Kim G，Johnson NR，et al. MicroRNAs from the parasitic plant Guscuta campestris target host messenger RNAs [J]. Nature，2018，553（7686）：82-85.
[17] Hines PJ. MicroRNAs in functional and dysfunctional pain [J]. Science，2017，356（6343）：1134-1136.
[18] Sambandan S，Akbalik G，Kochen L，et al. Activity-dependent spatially localized miRNA maturation in neuronal dendrites [J]. Science，2017，355（6325）：634-637.
[19] Cao H，Huang S，Liu A，et al. Up-regulated expression of miR-155 in human colonic cancer [J]. J Cancer Res Ther，2018，14（3）：604-607.
[20] Chen L，Yang X，Zhao J，et al. Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis [J]. J Exp Clin Cancer Res，2020，39（1）：94.
[21] Shao C，Yang F，Qin Z，et al. The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer：a systematic review with meta-analysis [J]. BMC Cancer，2019，19（1）：1103.
[22] Santos JC，Lima NDS，Sarian LO，et al. Exosome-mediated breast cancer chemoresistance via miR-155 transfer [J]. Sci Rep，2018，8（1）：829.
[23] Tao M，Zhou Y，Jin Y，et al. Blocking lncRNA MIR155HG/miR-155-5p/-3p inhibits proliferation，invasion and migration of clear cell renal cell carcinoma [J]. Pathol Res Pract，2020，216（2）：152803.
[24] Yan Y，Huang H. Interplay Among PI3K/AKT，PTEN/FOXO and AR Signaling in Prostate Cancer [J]. Adv Exp Med Biol，2019，1210：319-331.
[25] Costa RLB，Han HS，Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer：A review [J]. Breast Cancer Res Treat，2018，169（3）：397-406.
[26] Han B，Wang S，Zhao H. MicroRNA-21 and microRNA-155 Promote the Progression of Burkitt’s Lymphoma by the PI3K/AKT Signaling Pathway [J]. Int J Clin Exp Pathol，2020，13（1）：89-98.
